Economy March 5, 2026

Judge OKs $29 Million Payment to Pfizer in Settlement Linked to SAC Capital Insider-Trading Case

Agreement resolves a dispute over leftover funds from SAC’s $601.8 million settlement involving trades tied to Wyeth and Elan

By Jordan Park
Judge OKs $29 Million Payment to Pfizer in Settlement Linked to SAC Capital Insider-Trading Case

A federal judge approved a $29 million payment to Pfizer to resolve its challenge to the U.S. Securities and Exchange Commission’s distribution of leftover funds from the 2013 SAC Capital settlement. The award stems from $75.2 million remaining after SAC’s $601.8 million settlement tied to insider trading by former SAC employee Mathew Martoma; Pfizer agreed to drop its appeal and the U.S. Treasury will receive the balance.

Key Points

  • A federal judge approved a $29 million payment to Pfizer to resolve its dispute with the SEC over leftover funds from SAC Capital’s settlement.
  • The $29 million comes from $75.2 million remaining of SAC’s $601.8 million settlement connected to trades in Wyeth and Elan by Mathew Martoma, who was later sentenced to nine years for securities fraud and conspiracy.
  • Pfizer dropped its appeal after arguing a neurologist who tipped Martoma about a 2008 Alzheimer’s drug trial owed a fiduciary duty to Wyeth; the remaining $46.2 million will go to the U.S. Treasury.
  • Sectors impacted include pharmaceutical companies involved in M&A, securities enforcement and the hedge fund industry.

A federal judge has sanctioned a $29 million payment to Pfizer to end the company's dispute with the U.S. Securities and Exchange Commission related to the SEC's 2013 settlement with billionaire Steven A. Cohen's former hedge fund, SAC Capital Management.

U.S. District Judge Victor Marrero in Manhattan signed off on the payout on Thursday. The payment represents part of $75.2 million that remained after SAC's broader $601.8 million settlement addressing trades connected to Wyeth and Elan that were tied to Mathew Martoma, a former SAC employee who was later sentenced to nine years in prison following convictions for securities fraud and conspiracy.

Judge Marrero had previously determined, in a November 2024 ruling, that the entire $75.2 million should be remitted to the U.S. Treasury. That ruling rested in part on the finding that Wyeth - which Pfizer acquired in 2009 - was not a direct victim of Martoma's trades, according to the court's prior decision.

Pfizer contested that conclusion and appealed, arguing that it should receive the $75.2 million. The company's position was based on an assertion that a neurologist who provided a tip to Martoma in 2008 about an Alzheimer’s drug trial owed a fiduciary duty to Wyeth. Rather than continue the appeal, Pfizer agreed to abandon the challenge in exchange for the $29 million award.

Under the terms approved by the judge, the U.S. Treasury will receive the remaining $46.2 million of the $75.2 million pool. The settlement resolves the allocation dispute stemming from the SEC's enforcement action tied to SAC's settlement.

Steven A. Cohen himself was not criminally charged in the matter. The hedge fund he ran, SAC Capital Management, later changed its name to Point72 Asset Management in 2014.


Context and next steps

With the court's approval completed, Pfizer has received a portion of the remaining settlement funds and dropped its appeal. The remainder of the funds will be transferred to the Treasury as ordered by the court.

Risks

  • Legal uncertainty over the allocation of settlement funds - the dispute required judicial resolution and could prompt similar claims in other enforcement contexts, affecting the legal and compliance costs for pharmaceutical and financial firms.
  • Reputational and regulatory exposure for parties linked to insider trading cases - while Steven A. Cohen was not criminally charged, the matter involved lengthy litigation and a high-profile settlement that touches asset managers and institutional investors.
  • Residual financial distribution outcomes - allocation decisions by courts can shift recoveries between corporate claimants and the U.S. Treasury, creating uncertainty for companies seeking restitution in enforcement actions.

More from Economy

Judge Orders Start of Refunds for Trump-Era Tariffs; Analysts Put Potential Payouts Between $168bn and $182bn Mar 5, 2026 Markets Retreat as Middle East Conflict Sparks Energy, Inflation and Growth Concerns Mar 5, 2026 Trump Says U.S. Forces Have Degraded Iran’s Military Capabilities Mar 5, 2026 Middle East escalation and February inflation data set to shape U.S. markets next week Mar 5, 2026 U.S. Regulators Say Tokenized Securities Face Same Capital Rules as Traditional Securities Mar 5, 2026